Latest Articles

Publication Date
Immunotherapy Addition Demonstrates Sustained Survival Benefits in - Bioengineer.org

Immunotherapy Addition Demonstrates Sustained Survival Benefits in Bioengineer.org

Published: May 29, 2026, 11:56 p.m.
Gilberto Lopes: New Study Suggests Survival Benefit With GLP-1 RAs in Endometrial Cancer - Oncodaily

Gilberto Lopes: New Study Suggests Survival Benefit With GLP-1 RAs in Endometrial Cancer Oncodaily

Published: May 25, 2026, 7:06 p.m.
Antibody-Drug Conjugate Improves Survival for Endometrial Cancer Patients - Labroots

Antibody-Drug Conjugate Improves Survival for Endometrial Cancer Patients Labroots

Published: May 25, 2026, 10 a.m.
Lesion-centric reprogramming: hydrogel-enabled photothermal reset of endometriosis pain.

Endometriosis-associated pelvic pain represents a prototypical failure of systemic therapy for a locally organized, neuroinflammatory disease. Persistent pain arises from the convergence of estrogen-driven lesion survival, chronic inflammation, fibrosis, and …

Published: May 23, 2026, midnight
Is Recurrent Endometriosis a Reprogrammed Disease? Molecular Persistence Beyond Surgical Clearance.

Background: Endometriosis is traditionally conceptualized as a localized gynecological disorder characterized by the presence of ectopic endometrial tissue. However, high recurrence rates following apparently complete surgical excision challenge this lesion-based …

Published: May 21, 2026, midnight
New therapy bests chemo to improve survival in endometrial cancer - Rare Cancer News

New therapy bests chemo to improve survival in endometrial cancer Rare Cancer News

Published: May 20, 2026, 1:14 p.m.
Endometriosis-related alterations in the endometrium revealed by integrated single-cell and AI-powered approaches.

Endometriosis, affecting 1 in 9 women, presents treatment and diagnostic challenges. To address these issues, we generated a comprehensive single-cell atlas of endometrial tissue, comprising 466,371 cells from 35 endometriosis …

Published: May 20, 2026, midnight
Merck’s billion-dollar Kelun bet pays off as TROP2 improves survival in endometrial cancer - BioSpace

Merck’s billion-dollar Kelun bet pays off as TROP2 improves survival in endometrial cancer BioSpace

Published: May 19, 2026, 11:19 a.m.
Merck-Kelun ADC boosts survival in phase 3 endometrial cancer, stokes TROP2 race - CHOSUNBIZ - Chosunbiz

Merck-Kelun ADC boosts survival in phase 3 endometrial cancer, stokes TROP2 race - CHOSUNBIZ Chosunbiz

Published: May 19, 2026, 6:54 a.m.
Sacituzumab Tirumotecan Improves Survival in Advanced Endometrial Cancer - Targeted Oncology

Sacituzumab Tirumotecan Improves Survival in Advanced Endometrial Cancer Targeted Oncology

Published: May 18, 2026, 1:33 p.m.
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!